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Objective: We performed mitral valve replacement with a pulmonary autograft using the technique described by
us earlier and present the results.
Methods: Between August 2000 and July 2007, 19 patients (16 male patients; age, 30–58 years) with isolated
calcific mitral stenosis (n¼ 16) or mixed mitral stenosis and regurgitation (n¼ 3) underwent mitral valve replace-
ment with a pulmonary autograft. Sixteen patients were in New York Heart Association class III and 3 were in
New York Heart Association class IV preoperatively. Eight patients were in atrial fibrillation. The autograft im-
plantation was achieved by using a scalloped stent of polytetrafluoroethylene felt for external support of the
autograft. No anticoagulants were prescribed.
Results: There were 3 early deaths, one each caused by ventricular dysfunction, ventricular arrhythmias, and au-
tograft dehiscence requiring early reoperation. Follow-up of survivors ranged from 34 to 99 months (mean, 71.9
 18.2 months; median, 75 months). The mean valve area was 2.96  0.9 cm2 (range, 2.2–4.3 cm2). Fourteen
survivors are in New York Heart Association class I, and 2 are in NYHA class II; 4 continue to be in atrial fibril-
lation. Follow-up echocardiograms (n ¼ 16), magnetic resonance imaging (n ¼ 6), and cardiac catheterization
(n ¼ 4) have demonstrated no significant autograft and pulmonary homograft dysfunction. There were no late
deaths or reoperations or thromboembolic complications.
Conclusions: Mitral valve replacement with a pulmonary autograft, a complex operation, can be performed in
selected patients with acceptable results. The use of our technique of autograft implantation offers several advan-
tages and avoids exposure of the scaffold to the bloodstream.Mitral valve replacement with a pulmonary autograft (PA–
MVR) has been demonstrated to be a suitable option for
patients requiring surgical intervention for mitral valve dis-
ease. The advantages of this procedure include durability,
good hemodynamics, avoidance of anticoagulation, low in-
cidence of thromboembolic complications, and suitability in
the presence of infection. In a prior publication we presented
our surgical technique and initial results with this proce-
dure.1,2 Since then, our follow-up has increased, and we
now present more detailed results with a longer follow-up
in 19 consecutive patients over a 7-year period.
MATERIALS AND METHODS
Between August 2000 and July 2007, 19 patients (Table 1) underwent
PA–MVR. All these patients had rheumatic mitral valve disease not amena-
ble to mitral valve repair. Preoperative transthoracic echocardiographic
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doi:10.1016/j.jtcvs.2008.11.063The Journal of Thoracic and Canalysis was performed in all patients and revealed severe rheumatic mitral
stenosis with a mitral valve area of less than 1.0 cm2 in 15 patients; 1 patient
had a mitral valve area of 1.2 cm2. Mitral valve calcification was seen on
fluoroscopic analysis in 16 patients. Combined mitral stenosis and mitral re-
gurgitation was present in 3 patients. Three patients had evidence of a throm-
bus in the left atrium and were receiving oral anticoagulants. Insignificant
aortic regurgitation was present in 2 patients. Three patients had moderate
tricuspid regurgitation caused by pulmonary arterial hypertension. Mean
left atrial (LA) size was 51.4  9.9 mm (range, 39–84 mm; median, 48
mm). Four patients had LA sizes of between 39 and 45 mm, 6 patients
had LA sizes of between 46 and 50 mm, 7 patients had LA sizes of between
51 and 60 mm, and 2 patients had LA sizes of greater than 60 mm. The mean
left ventricular end-systolic dimension was 21.1  4.4 mm (range, 25–40
mm; median 28 mm), and the mean left ventricular end-diastolic dimension
was 46.5 9.3 mm (range, 34–80 mm; median, 45 mm). The mean left ven-
tricular ejection fraction was 58.4%  3.9% (range, 55%–70%; median,
60%). Cardiac catheterization and cineangiography were performed if there
was suspicion of associated aortic valve or coronary artery disease. All these
patients had evidence of severe pulmonary hypertension (mean pulmonary
artery pressure, 67 mm Hg) and severe pulmonary venous hypertension
(mean pulmonary capillary wedge pressure, 36 mm Hg).
Patient Selection
Informed consent was obtained from all patients. We offered this proce-
dure only to rheumatic subjects more than 30 years of age because of con-
cerns of involvement of the pulmonary valve with the rheumatic disease
process, which we observed in our prior experience with aortic valve re-
placement with a pulmonary autograft.3 The procedure was not considered
in patients with a bicuspid pulmonary valve or pulmonary regurgitation.
Other exclusion criteria included (1) previous reoperation because the har-
vesting of the autograft might be difficult as a result of adhesions, (2) asso-
ciated aortic valve disease requiring intervention, (3) associated coronaryardiovascular Surgery c Volume 138, Number 2 359
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AF ¼ atrial fibrillation
LA ¼ left atrial
MRI ¼ magnetic resonance imaging
MVR ¼ mitral valve replacement
PA–MVR ¼ mitral valve replacement with a
pulmonary autograft
artery disease, (4) significant left ventricular dysfunction, (5) requirement of
an emergency operation, (6) requirement of reoperation for prosthetic valve
endocarditis, (7) presence of native valve endocarditis with significant left
ventricular dysfunction, and (8) age greater than 60 years (bioprostheses
were preferred in these patients). Preoperative atrial fibrillation (AF) was
not a contraindication. A small left atrium was not a contraindication, and
10 of the 19 patients had LA sizes of less than 50 mm. This might, however,
be an important consideration in the pediatric age group when this operation
is offered to children with congenital mitral stenosis.
Intraoperative transesophageal echocardiographic analysis was per-
formed with a Hewlett–Packard Sonos 1500, 2500, or 5500 ultrasound
system (Hewlett–Packard Co, Andover, Mass). The echocardiographic as-
sessment included a systematic study of the annulus, leaflet thickness and
mobility, commissural and chordal fusion, presence of calcification,
regurgitant jet, thickness of the chordae tendinae, and presence of clots in
the left atrium or the LA appendage. Other valves were also assessed in
a systematic fashion. Special attention was directed to the pulmonary valve
because a bicuspid pulmonary valve or pulmonary regurgitation was
a contraindication.
Surgical Technique
For more information on surgical technique, see Figures 1 and 2. The
surgical approach was through a median sternotomy and vertical pericar-
diotomy in all patients. The pulmonary artery was dissected and looped.
Moderately hypothermic (28C) cardiopulmonary bypass was established,
and cold antegrade cardioplegia and topical cooling were used for myocar-
dial preservation. After a left atriotomy, the LA thrombus, if present, was
removed. The mitral valve was inspected, and if repair was not feasible, it
was excised with preservation of both the anterior and posterior chordae
and subvalvular apparatus in all patients by using the technique of Miki
and colleagues.4 The pulmonary autograft was then harvested in a standard
fashion and sized with a homograft sizer. The technical details of PA–MVR
were described by us in detail earlier1; however, the salient features are
summarized.
We did not place the autograft in a prosthetic tube, as advocated by
others.5,6 Instead, an appropriately sized stent was prepared with thick,
nonporous Teflon felt (CR Bard, Inc, Delran, NJ), the circumference of
which was measured with an appropriate sizer. Its height was measured
to adjust to the height of the pulmonary valve commissures. When the
stent ends were closed, this formed a ring support for the autograft.
Three interrupted sutures were passed through the mitral annulus at
equidistant points and then into the top of the autograft commissures.
After this, the autograft was inverted into the left ventricle and sutured
to the mitral annulus with a continuous suture. Sutures were then passed
from the autograft commissures 2 mm below the pillars and into the Tef-
lon stent and through the LA wall, which was gathered 2 cm upstream
of the mitral annulus. After running the sutures in a continuous fashion
and tying them, the ring stent was incorporated between the autograft
and the LA wall without being exposed to the bloodstream. The newly
created mitral valve was now tested for competence by injecting cold
saline into the left ventricular cavity with a bulb syringe with the aortic
root vent open, and coaptation of leaflets was observed. The left atrium360 The Journal of Thoracic and Cardiovascular Suwas closed, and the right ventricular outflow tract was reconstructed
with an appropriately sized cryopreserved pulmonary homograft from
our own valve bank (Table 2). Immediate postoperative transesophageal
echocardiographic analysis was performed in all the patients to confirm
that the autograft and homograft were functioning satisfactorily. The
mean aortic crossclamp and cardiopulmonary bypass times were 118.6
 17.2 minutes (range, 63–140 minutes) and 145.2  13 minutes
(range, 119–174 minutes), respectively.
No surgical procedure was performed for AF. However, internal cardio-
version was attempted in all patients with AF on the operating table by
using direct internal defibrillator paddles connected to an external DC
defibrillator.
Follow-up
Before discharge from the hospital, transthoracic echocardiographic
analysis was performed in all patients, and this procedure was repeated at
6-month intervals. Mitral regurgitation was graded as none, mild, moderate,
or severe according to published criteria.7 Autograft degeneration was con-
sidered as valve area less than 1.5 cm2 or more than mild regurgitation
through the autograft. The pulmonary homograft was also assessed, and
peak gradients of less than 20 mm Hg across the pulmonary valve were
considered mild pulmonary stenosis. A peak transvalvular gradient of 50
mm Hg or greater across the pulmonary valve was considered significant
pulmonary stenosis.
No anticoagulants or antiplatelet drugs were prescribed. All patients
less than 45 years of age with rheumatic heart disease received long-acting
benzathine penicillin until 45 years of age. All patients received itraconazole
for 6 weeks after surgical intervention as prophylaxis against fungal endo-
carditis.
Statistical Analysis
Statistical analysis was performed with the SPSS for windows 11.5 soft-
ware package (SPSS, Inc, Chicago, Ill). Descriptive statistics (ie, mean and
standard deviation) have been calculated for the continuous variables. Free-
dom from valve-related events and actuarial estimates have been calculated
by using the Kaplan–Meier analysis. A valve-related event was defined as
any episode of thromboembolism, hemorrhage, congestive heart failure, in-
fective endocarditis, structural deterioration, or significant gradients, as per
published criteria.8 The period between July 2007 and June 2008 was the
closing interval for the study, and the follow-up status of the patients during
this period was used for statistical analysis.
TABLE 1. Profile of patients undergoing mitral valve replacement
with the pulmonary autograft
Male/female sex 14/5
Age (y) 30-58 (mean, 42.8  7.8; median, 40)
Symptoms
Dyspnea 19 (100%)
Palpitations 16 (84.2%)
CHF 12 (63.2%)
NYHA class
III 16 (84.2%)
IV 3 (15.8%)
Clinical diagnosis
Calcific mitral stenosis 16 (84.2%)
Mitral stenosisþ regurgitation 3 (15.8%)
Moderate TR 3 (15.8%)
Atrial fibrillation 8 (42%)
CHF, Congestive heart failure; NYHA, New York Heart Association; TR, tricuspid
regurgitation.rgery c August 2009
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Hospital Mortality
All patients could be uneventfully weaned off cardiopul-
monary bypass with satisfactory autograft function on trans-
esophageal echocardiographic analysis. However, there
were 3 early deaths. The first death occurred in a 34-year-
old patient who had acute pulmonary edema caused by se-
vere mitral regurgitation on the third postoperative day. At
the time of reoperation, dehiscence of the proximal suture
line was observed and successfully repaired. However, the
patient experienced irreversible myocardial failure and
died. The second death occurred in a 50-year-old patient
who had an uneventful postoperative course and experi-
enced sudden intractable ventricular tachyarrhythmia on
the 10th postoperative day and died. The third death oc-
curred in a 38-year-old patient who died on the fourth post-
operative day as a result of severe biventricular dysfunction.
In all 3 patients, permission for autopsy was denied by the
family.
Early Reoperation
As detailed above, 1 patient required reoperation for auto-
graft dehiscence. Two patients required reoperations for ex-
cessive mediastinal bleeding. In one of these patients, the
bleeding source was the raw surface of the posterior wall
of the right ventricular outflow tract, and in another patient
it was from the edges of the pleura.
Hospital Course
Apart from the above, the other patients had an uneventful
postoperative course. Of the 8 patients with preoperative AF,
sinus rhythm was restored in 4, and the rest continued to be
in AF. Minor sternal wound infection was encountered in 1
patient. The mean intensive care unit stay was 2.8 1.7 days
FIGURE 1. The stent designed from thick, nonporous Teflon felt. Reprin-
ted from J Thorac Cardiovasc Surg. 2001;122:378-9. Copyright 2001 with
permission from the American Association for Thoracic Surgery.The Journal of Thoracic and(range, 2–6 days; median, 2 days), and the mean hospital
stay was 7.9 2.8 days (range, 5–15 days; median, 7 days).
Follow-up
All patients were seen in the outpatient clinic at 6-month
intervals and underwent clinical examination and echocar-
diographic analysis. Between December 2007 and June
2008, the records of all the patients were obtained, and their
most recent status during this period was analyzed for report-
ing the results. The follow-up data (100% complete) ranged
from 34 to 99 months (mean, 71.9  18.2 months; median,
75 months) and totaled 95.9 patient-years. Among survivors,
9 (56.3%) were followed up for 6 or more years, 3 (18.7%)
were followed for 5 or more years, and 4 (25%) were fol-
lowed up for more than 2 years.
FIGURE 2. Diagram of the completed autograft implantation. Reprinted
from J Thorac Cardiovasc Surg. 2001;122:378-9. Copyright 2001 with per-
mission from the American Association for Thoracic Surgery.
TABLE 2. Intraoperatively measured size of the pulmonary
autografts and pulmonary homografts
Size (mm) Pulmonary autograft (n) Pulmonary homograft size (n)
24 3 5
26 5 9
28 6 4
29 1 
30 4 1Cardiovascular Surgery c Volume 138, Number 2 361
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Outflow Tract
Echocardiographic data at the time of discharge from the
hospital and at follow-up in the closing interval are presented
in Table 3. It is apparent that the autograft performed well,
with no evidence of degeneration. Similarly, there was no
pulmonary stenosis or regurgitation.
Six patients consented to magnetic resonance imaging
(MRI) and 4 to cardiac catheterization and cineangiography.
MRI findings in these patients are particularly interesting.
As described by us earlier,9 it clearly shows the autograft
wholly in the left atrium, which extends at least 2 cm up-
stream of the mitral annulus. Therefore the valve cusps of
the autograft are at a higher level compared with the tricus-
pid valve, as seen in these images (Figure 3). Echocardiog-
raphy, MRI, and cineangiography have clearly demonstrated
no significant autograft and pulmonary homograft dysfunc-
tion.
Survival and Functional Status
There were no late deaths. Fourteen survivors are in New
York Heart Association class I, and 2 are in NYHA class II;
4 continue to be in AF. There were no thromboembolic com-
plications, hemolysis, or infective endocarditis in the survi-
vors, and no reoperations were required in the follow-up
period.
The actuarial and event-free survival (Figure 4) at a me-
dian follow-up of 75 months was 89.47% 7% (95% con-
fidence interval, 75%–98%).
DISCUSSION
An ideal substitute for the irreparable mitral valve has not
yet been found. As for a valve substitute in any position,
such a substitute should be easily available, be inexpensive,
provide hemodynamics comparable with those of the natural
human mitral valve, have the ability to remodel, and be re-
sistant to infection and must not propagate thromboemboli
and be free from the hazards of anticoagulation. In growing
children it should grow with the patient. In pursuit of this
goal, Ross first described the PA–MVR (Ross II procedure)
TABLE 3. Postoperative echocardiographic findings in 16 survivors
undergoing mitral valve replacement with the pulmonary autograft
Parameter Before discharge At last follow-up
Mitral valve area (cm2) 3.15  0.8 (2.2–4.8) 2.96  0.9 (2.2–4.3)
Mitral stenosis None None
Mean mitral gradient (mm Hg) 4  0.2 (1–4) 3.4  1.5 (2–5)
Mitral regurgitation
None 15 12
Mild 1 3
Moderate 0 1
PA peak gradient (mm Hg) 10  7.9 (0–20) 15  8.5 (10–20)
Pulmonary regurgitation None None
PA, Pulmonary artery.362 The Journal of Thoracic and Cardiovascular Suin 1967.10 He subsequently performed 8 such procedures be-
tween 1967 and 1971, and in 1997, 4 of the 7 patients were
asymptomatic and reoperation free for more than 10 years.11
Yacoub and Kittle12 used an aortic homograft placed inside
a Dacron tube for mitral valve replacement (MVR), and
Elkins13 used a pulmonary homograft for this purpose.
However, the techniques of PA–MVR were popularized
by Kabbani and coworkers,5,11,14 who have aggressively
pursued this operation and have described its technical as-
pects in great detail. This operation has since been adopted
by many groups, and experience with these patients
FIGURE 3. Gradient echocardiographic pulse sequence (true-FISP) cine
magnetic resonance image in the 4-chamber view (diastolic frame): the pul-
monary autograft is shown in the mitral position (arrow). Note the level of
the new ‘‘mitral valve,’’ which is higher than that of the tricuspid valve. RV,
Right ventricle; RA, right atrium; LV, left ventricle; LA, left atrium. Reprin-
ted from Tex Heart Inst J. 2004;31:326-7. Copyright 2004 with permission
from the Texas Heart Institute Journal.
FIGURE 4. Event-free survival in patients undergoing the Ross II
procedure.rgery c August 2009
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cally demanding, failures have occurred and have been dealt
with by instituting a number of technical modifications. The
initial procedures were performed by using the ‘‘top-hat
technique,’’12 with the autograft being completely placed
in the left atrium rather than the left ventricle to facilitate eas-
ier suturing and to prevent left ventricular outflow tract ob-
struction. As pointed out by Kabbani and colleagues,14 the
Achilles heel of this operation is conduit obstruction caused
by angulation of the soft Dacron tubing material inside
which the autograft is placed. The ‘‘miniskirt’’ technique
was proposed in which the pericardium is placed over the
woven Dacron graft to minimize this.17 This saved operative
time and was considered low risk. Current modifications in-
clude the use of surgical glue in this miniskirt pericardial
configuration in between the Dacron and the pericardial tis-
sue to achieve firmness.14
We have not used this technique and have developed our
own technique in which a stent fashioned out of Teflon felt is
used to support the autograft. There are a number of advan-
tages of this technique. There is no risk of kinking of the Da-
cron tube, which can produce immediate autograft failure.
The stent is completely buried and does not come into con-
tact with the bloodstream, thus minimizing the risk of throm-
boembolic complications. Prophylactic anticoagulants are
therefore not required, which is a major advantage. Al-
though we have not performed this procedure in children,
the advantage of avoiding anticoagulants, even in the short
term, in children is important. We have also observed the au-
tograft sinuses to billow during valve closure in the ventric-
ular systole on echocardiographic analysis, which might
indicate that this technique might help in the growth poten-
tial of the autograft, an advantage that might not be obtained
when the autograft is encased in a tube. Making slits in the
side of the tubing has been reported to preserve the growth
potential, particularly in children; however, long-term fol-
low-up data are not available to demonstrate this advantage.
Concerns have been voiced on the growing popularity of
PA–MVR.18 Long-term follow-up data are not available,
although Kabbani and colleagues14 have recently reported
a freedom from autograft degeneration of 93.4% at 5 years’
follow–up. Others have also reported encouraging re-
sults.6,15,16 In the older age group bioprostheses are still
the substitutes of choice because they are technically easier
to implant, with a lower operative risk and proved long-term
results.19 Although Kabbani and colleagues14 project similar
durability when compared with bioprostheses, there is no
firm clinical evidence to this effect. The issue of long-term
durability compared with that of a bioprosthesis will only
become clear with longer follow-up. Also, there is no evi-
dence presently that the autograft is resistant to infective en-
docarditis because deaths have been reported as a result of
this complication. However, PA–MVR is free from some
of the disadvantages of the bioprosthesis, namely rapid de-The Journal of Thoracic and Cgeneration in younger patients, the presence of a high-profile
stent, less effective orifice area in small sizes, and the possi-
bility of left ventricular outflow tract obstruction and rhythm
disturbances in patients with smaller hearts.6
This procedure might be suitable for children in whom
other valve substitutes are not the preferred option, although
its growth in children has not been studied. We are in agree-
ment with the experience of others that PA–MVR is a suit-
able option for a select group of patients with rheumatic
mitral valve disease, particularly in developing countries.
The operation can be accomplished at a much reduced cost
compared with the use of prosthetic valves and avoids the
costs and hazards of anticoagulation. In many developing
countries the majority of the patients live in rural areas and
have limited or no access to centers in which anticoagulation
can be reliably monitored. Freedom from anticoagulation
eliminates the risk of anticoagulant-related hemorrhage
and also prosthetic valve dysfunction and sudden death
caused by inadequate anticoagulation, as seen with mechan-
ical prostheses. The procedure does take much longer to
perform than MVR with a mechanical prosthesis or a bio-
prosthesis, but the costs in the longer term are much less
because of avoidance of anticoagulation, need to travel to
distant hospitals for conducting tests to monitor anticoagula-
tion, and elimination of the risks of anticoagulant-related
hemorrhage, which might impose significant morbidity and
keep patients away from work. We do not regard preopera-
tive AF as a contraindication to this operation, and we do
not prescribe oral anticoagulants, even to those patients
who continue to remain in AF. We have followed this policy
successfully over the last decade in patients undergoing mi-
tral valve repair and MVR with bioprostheses and have not
observed any deleterious effects.20,21
The final concern is that of converting a single-valve op-
eration into a 2-valve procedure because of the placement of
a pulmonary homograft. However, our midterm to long-term
results of the Ross operation for aortic valve disease22 have
not demonstrated any significant degeneration of the con-
duits in the pulmonary position, and this has encouraged
us to offer this procedure to rheumatic patients with mitral
valve disease not amenable to repair. We have, however,
not used this operation in patients younger than 30 years be-
cause of concerns about the involvement of the pulmonary
valve by the rheumatic process.
Limitations
An important limitation of our study is that the patient
population is highly selected, and the number of patients is
small. Availability of homografts is the limiting factor in
our present practice, and we might be able to increase the
number of these procedures once a regular supply of homo-
grafts is assured. When homografts are procured and pre-
served locally by developing valve banks, further
reduction can be made in the cost of this procedure byardiovascular Surgery c Volume 138, Number 2 363
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perience with this operation in the pediatric age group. The
operation is technically complex and is associated with
a learning curve. Once these limitations are overcome, the
procedure is very cost-effective. We had 3 deaths in 19
patients, and in one of these 3, death was due to autograft
dehiscence in the early part of our experience. The other 2
deaths were due to ventricular arrhythmia and severe biven-
tricular dysfunction and were probably not related to the
choice of the substitute because both these patients had se-
vere pulmonary hypertension. The mortality also appears
to be disproportionately high because of the small number
of patients. However, we do believe that with increasing
experience, mortality can be brought down, as indicated by
Kabbani and colleagues,14 who report a mortality of only
4.5% in their large experience.
CONCLUSION
PA–MVR, a complex operation, can be performed in
selected patients with acceptable results. The use of our tech-
nique of autograft implantation offers several advantages.
We thank our colleagues from the Department of Cardiology for
the meticulous follow-up echocardiographic evaluation of these
patients.
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